Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Bayer takes legal battle over Roundup cancer claims to U.S. Supreme Court

08/16/2021 | 11:30am EDT
FILE PHOTO: Bayer unit Monsanto Co's Roundup shown for sale in California

FRANKFURT (Reuters) -Bayer, trying to contain billions of dollars in legal costs, filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the German group's glyphosate-based weedkillers.

Bayer last week lost a third appeal against verdicts that sided with users of glyphosate-based Roundup, awarding them tens of millions of dollars each, leaving the drugs and pesticides group to pin hopes for relief on the United States' top court.

Bayer on Monday asked the Supreme Court to review one such verdict by the federal 9th U.S. Circuit Court of Appeals that found in favour of California resident and Roundup user Edwin Hardeman, it said in a statement.

The maker of aspirin, Yasmin birth-control pills and stroke prevention drug Xarelto has repeatedly argued that the cancer claims over Roundup go against sound science and product clearance from the federal environmental regulator.

"The Ninth Circuit's errors mean that a company can be severely punished for marketing a product without a cancer warning when the near-universal scientific and regulatory consensus is that the product does not cause cancer, and the responsible federal agency has forbidden such a warning," the company said.

Roundup-related lawsuits have dogged the company since it acquired the brand as part of its $63 billion purchase of agricultural seeds and pesticides maker Monsanto in 2018.

Bayer struck a settlement deal in principle with plaintiffs last year but failed to win court approval for a separate agreement on how to handle future cases, as it intended to keep the product on the market.

Last month, it took an additional litigation provision of $4.5 billion to cover any unfavourable ruling by the Supreme Court. That came on top of $11.6 billion it previously set aside for settlements and litigation over the matter.

Among other measures to contain the legal onslaught, Bayer plans to replace glyphosate in weedkillers for the U.S. residential market with other active ingredients.

It will, however, continue to sell the herbicide to farmers, who rely on it heavily, and whose role in the litigation has been described as negligible by Bayer.

(Reporting by Ludwig Burger; editing by Douglas Busvine and Jonathan Oatis)


© Reuters 2021
Latest news "Economy & Forex"
05:55pRogers family boardroom drama unlikely to impact deal to buy Shaw
RE
05:52pLIVESTOCK-CME live cattle falls as cash market idles
RE
05:47pS&P snaps 7-day winning streak amid taper talk
RE
05:41pRoche's implant for chronic eye disorder wins U.S. approval
RE
05:41pSPAC linked to Trump's social media venture surges for second day
RE
05:40pToronto market rises for third week as energy shares rally
RE
05:38pBristol Myers interested in buying Aurinia Pharma - Bloomberg News
RE
05:37pDow posts record closing high, stocks gain for 3rd week; dollar dips
RE
05:35pEuro Gains 0.41% to $1.1647 -- Data Talk
DJ
05:35pThe WSJ Dollar Index Falls 0.37% to 88.05 -- Data Talk
DJ
Latest news "Economy & Forex"